biostudies-literatureBaker DLNCI NIH HHS1313-23https://www.ebi.ac.uk/biostudies/studies/S-EPMC2993160biostudies-literatureUnknown363(14)<h4>Background</h4>The survival rate among patients with intermediate-risk neuroblastoma who receive dose-intensive chemotherapy is excellent, but the survival rate among patients who receive reduced doses of chemotherapy for shorter periods of time is not known.<h4>Methods</h4>We conducted a prospective, phase 3, nonrandomized trial to determine whether a 3-year estimated overall survival of more than 90% could be maintained with reductions in the duration of therapy and drug doses, using a tumor biology-based therapy assignment. Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathologicalThe New England journal of medicineOutcome after reduced chemotherapy for intermediate-risk neuroblastoma.PMC2993160U10 CA098543UI0-CA98543UI0-CA29139U10 CA029139UI0-CA98413U10 CA017829U10 CA098413Maris JMJohn HDouglas HBostrom BGranger MLenarsky CKreissman SKuttesch JLarsen EEstrada JTermuhlen ADickens DFurman WReynolds CPWeinblatt MSeeger RCTaylor JShimada HCairney AJohnson MCGrewal SKuerbitz SOzkaynak MShen VFrantz CShamberger RCLook ATBarnette PFeusner JRavindranath YSamson YFallon RBrecher MRodriguez-Galindo CDrachtman RCohn SLWalterhouse DBoklan JChildren’s Oncology GroupSilva MYanofsky RBertolone SJohnston JBalis FRicafort RBernstein JBecton DMcLean TYu LChatchawin AWittman BPrasannan LArndt CChristopher MCole CTurner CKobrinsky NIrving HMain CBassem RLee AHetherington MYork TStein DThomas PHalton JKiley VChang EGowda NTekautz TCherrick IMcMahon DKelly MKatzenstein HStroud CDe Santes KPais RFerguson WLondon WBAppel BNeglia JArceci RAmmann RMcDonough CMitchell TFelgenhauer JMatthay KKBroxson EGera RArlene RFu CChaffee SLoew TBryant PMcCowage GGreenwood MLee YHanif IDaghistani DRitchey AKupfer GPortwine CKumar MCastleberry RPKirkpatrick GRoberts WLowe ESchmidt MHomans AMatloub YJWeinstein HAshley DHand JDaniel GMcNall-Knapp RIsakoff MSelsky CNeely JLuis CKeuker CChauvenet AReddy ASchmidt MLSalvi SDucore JAtkinson MLockhart SBedros ADome JPerentesis JSalman ECrouse VMcManus MGodder KBond MOlson JKwon JHKanwar VGrant RSchorin MHackney LStrother DKraveka JGold SFinklestein JMaloney KBaker DLHayashi RBuxton AJoseph WSchwartz CGoldsby RWinick NSandler AWinter SMichon BCohn SLouie RSmith ALobel JMascarenhas LStram DKretschmar CJasty RTannous RSandler EKamalakar PShad ADesai SJSmith SMarina NScher CMody RCameron TBeck Popovic MBomgaars LMegason GfalseOutcome after reduced chemotherapy for intermediate-risk neuroblastoma.<h4>Background</h4>The survival rate among patients with intermediate-risk neuroblastoma who receive dose-intensive chemotherapy is excellent, but the survival rate among patients who receive reduced doses of chemotherapy for shorter periods of time is not known.<h4>Methods</h4>We conducted a prospective, phase 3, nonrandomized trial to determine whether a 3-year estimated overall survival of more than 90% could be maintained with reductions in the duration of therapy and drug doses, using a tumor biology-based therapy assignment. Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological2010-01-01T00:00:00Z2010 Sep2026-04-30T23:35:05.259Z2019-03-27T00:36:58ZS-EPMC29931602087988010.1056/NEJMoa100152710.1056/nejmoa1001527